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Galanin is a stress-inducible neuropeptide and cotransmitter in
serotonin and norepinephrine neurons with a possible role in
stress-related disorders. Here we report that variants in genes for
galanin (GAL) and its receptors (GALR1, GALR2, GALR3), despite
their disparate genomic loci, conferred increased risk of depression
and anxiety in people who experienced childhood adversity or
recent negative life events in a European white population cohort
totaling 2,361 from Manchester, United Kingdom and Budapest,
Hungary. Bayesian multivariate analysis revealed a greater rele-
vance of galanin system genes in highly stressed subjects com-
pared with subjects with moderate or low life stress. Using the
same method, the effect of the galanin system genes was stronger
than the effect of the well-studied 5-HTTLPR polymorphism in the
serotonin transporter gene (SLC6A4). Conventional multivariate
analysis using general linear models demonstrated that interac-
tion of galanin system genes with life stressors explained more
variance (1.7%, P = 0.005) than the life stress-only model. This
effect replicated in independent analysis of the Manchester and
Budapest subpopulations, and in males and females. The results
suggest that the galanin pathway plays an important role in the
pathogenesis of depression in humans by increasing the vulnera-
bility to early and recent psychosocial stress. Correcting abnormal
galanin function in depression could prove to be a novel target for
drug development. The findings further emphasize the importance
of modeling environmental interaction in finding new genes
for depression.
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Major depressive disorder (MDD) is a common and seriousdisease afflicting more women than men, and a leading
cause of disability worldwide, associated with much suffering and
major costs for society (1, 2). Environmental psychosocial stressors
are important in pathogenesis, because episodes are usually pre-
ceded by adverse life events, and early childhood experiences of
physical and emotional abuse and parental neglect are important
vulnerability factors (3, 4). Genetic vulnerability is significant with
a heritability of about 35% (5). We remain ignorant about the
brain processes that translate these genetic and environmental
influences into depressive symptoms or risk. A major clue is that
effective antidepressant drugs act directly or indirectly to en-
hance neurotransmission in serotonin (5-HT) and norepineph-
rine monoamine pathways, proving the monoamine hypothesis
of depression (6–8). Many other candidate mechanisms have
been identified in anatomical, pharmacological, and behavioral
studies of stress in rodents. However, the demonstration of state-
or trait-related abnormalities in human monoamine or other
neural systems remains frustratingly elusive, despite modern
brain-imaging methods. To determine whether the neuropeptide
galanin has a role in depression, we used a unique Bayesian
systems-based analysis to dissect out the influence of variation in
genes for the peptide and its receptors on the interaction be-
tween different psychosocial stressors and risk of depression.
Current drug treatment of depression is far from satisfactory;
the drugs target a limited range of monoamine mechanisms, they
have an appreciable side-effect burden, and response is often
partial (8, 9). In the search for better antidepressants, much at-
tention has focused on neuropeptides and their receptors, the
most diverse neurotransmitter system in the brain (8, 10–21),
which includes galanin. As yet, however, there is no compelling
evidence of efficacy of the neuropeptide approach or that par-
ticular peptides are involved in the pathogenesis of MDD.
Galanin, a 29-aa (30 in humans) peptide (22), is widely dis-
tributed in the rodent (23, 24) and human (25–27) brain. In rat
it coexists with noradrenaline (NA) in the locus coeruleus (LC)
and with 5-HT in the dorsal raphe complex (28). Like other
peptide cotransmitters (29), it is released when neurons fire
in high-frequency bursts in response to strong behavioral and
pharmacological challenge (30–32). Galanin exerts its action via
three cloned receptors, GALR1, GALR2, and GALR3 (33, 34)
with a broad distribution in rat (35) and primate brain (26, 36).
Animal behavioral studies (31, 32, 37–41) and a single study in
humans (42) suggest that galanin has a role in stress, depression-
like behavior, and anxiety. In addition, there is indication from
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previous genetic studies on humans that the galanin system is
involved in psychiatric disorders including alcoholism/addiction
(43–47), panic disorder (48, 49), and chronic pain-associated
depression (50). Furthermore, recent functional studies provided
the first evidence that polymorphisms in a highly conserved
genetic region upstream from the GAL gene regulates GAL
expression in brain areas, such as the amygdala and hypothala-
mus, implicated in the pathogenesis of depression (51, 52).
Genetic studies have the potential to identify molecular
mechanisms of MDD vulnerability (53), but even mega- and
meta-analyses of large genome-wide association studies (GWAS)
have not identified genetic variants associated with MDD that
survive genome-wide statistical correction (54, 55). Nominally
significant associations will include many false-positives. Never-
theless it is noteworthy that SNPs in the gene for galanin (GAL)
were among the top 10 genes whose variation was associated
with MDD in a recent GWAS (55). One way to improve sensi-
tivity is to take a system-based approach: if galanin is mecha-
nistically involved in depression, genetic variation in the peptide
and its receptors should exert similar influences, despite the fact
the genes are located on entirely different chromosomes without
linkage disequilibrium (LD) and with a low probability of ran-
domly similar effects. Others have argued that improved sensitivity
will come from deeper phenotyping (56) and characterization of
environmental factors (3, 4, 57), because neither genetic nor
environmental factors can be identified in isolation, if they modify
each other’s action to a high degree. Combining these two ap-
proaches, and in view of its preclinical properties, we predicted
that variation in galanin genes would strongly interact with envi-
ronmental stress in determining depression vulnerability. How-
ever, including more phenotypic and environmental variables ex-
acerbates the problem of false-positives from multiple comparisons.
Consequently, analyses of gene–environment interactions in-
volving multiple phenotypes face a similar burden as GWAS in
terms of correction for multiple testing. Furthermore, the con-
ditional nature of such interactions frequently leads to separate
analysis of multiple subpopulations (i.e., to even more statistical
tests). To cope with multiple hypothesis testing, we applied a
Bayesian systems-based approach both at structural and parametric
levels, which allows multiple correlated outcomes. This approach
supported the joint exploration of the underlying mechanism at
genotype, haplotype, and diplotype levels in different depression-
related phenotypes, and we validated the results by conventional
multivariate analysis using independent subsamples.
Results
Genetic Association and Gene × Environment Interaction Analysis
with Linear and Logistic Regression. Table 1 summarizes the de-
mographic and phenotypic characteristic of the studied pop-
ulation. To show the genetic effects alone or in interaction with
environmental factors, the effects of single SNPs (SI Methods,
Figs. S1–S4, and Table S1) and their combination (haplotypes,
HT) (Table S2) were studied. First, we carried out a traditional
linear and logistic regression analysis using additive genotypic
and diplotypic models for the selected variables. (For power
calculations see SI Methods and Table S3.) Of the 12 SNPs
studied, 7 statistically associated with one or more of the three
clinical phenotypes (Fig. 1). Furthermore, all but one (GAL
rs3136541) of the seven acted through interaction with either
childhood adversity or recent life events. Two of the six GALR1
SNPs interacted with recent life events (rs1893829, rs1162010)
and two with childhood adversity (rs5375, rs11665337) to influence
phenotypes. Three GALR1 haplotypes (HT2:GAGTAG, HT6:
GAGTGA, HT12:GGTCGG) interacted with childhood adver-
sity and one with recent life events (HT10:AAGCAG). The
single SNP representing GALR2 (rs8836) interacted with life
events, whereas a GALR3 SNP (rs2285179) and the main hap-
lotype (HT1:GA) interacted with childhood adversity. These
nominally significant findings can be seen in Tables S4 and S5,
which summarize all of the regression results. The results sug-
gested to us that GALR1 and probably GALR3 modulate neu-
rodevelopmental processes relevant to the effects of childhood
adversity, whereas GALR2 might modulate neuroplastic changes
connected with stress responses to recent life events. Despite
their interest and the corroboration that functionally related,
genomically distant genes show similar gene-by-environment
(G×E) interactions, these nominally significant effects did not
survive Bonferroni correction for multiple testing. To reach an
optimal correction for multiple-hypotheses testing concerning
the numerous potential dependencies between multiple pre-
dictors and phenotypes, we applied a systems-based approach in
the second phase using the Bayesian model averaging framework
(58–60). This approach allowed the principled and detailed in-
vestigation of G×E interactions as model properties. The anal-
ysis consisted of a joint multivariate analysis of GAL, GALR1,
GALR2, and GALR3 genes on all three phenotypes—reported
lifetime depression, current depression, and anxiety—both in
the Bayesian and conventional (traditional regression) sta-
tistical framework.
Bayesian Network-Based Bayesian Multilevel Analysis of Relevance.
Bayesian network-based Bayesian multilevel analysis (BN-BMLA)
was carried out using a method that allows a detailed investigation
of the relevance of factors with respect to multiple dependent
variables such as phenotype descriptors (61). The resulting scores
are posterior probabilities of relevance (Pr) ranging from 0 to 1.
This method involves Bayesian model averaging over possible
models reflecting relationships between variables, thus handling
the multiple hypothesis testing problem optimally by taking into
consideration the potential interdependencies of the predictors (for
detailed description of the BN-BMLA method, see SI Methods).
Fig. 1. Summary figure of the SNP association and SNP × environment in-
teraction results. This figure shows the −log P values (vertical axis) of the
genetic main effects (G), gene and childhood adversity interaction (G×CHA),
and gene and recent negative life events interaction (G×RLE) analysis (ad-
ditive genetic model in PLINK v1.07, http://pngu.mgh.harvard.edu/purcell/
plink). The red line represents P = 0.05 nominal significance level; above that
line significant results can be seen. Outcome variables were lifetime de-
pression (DEP), current depression scores (BSIDEP), and current anxiety scores
(BSIANX). Age and sex were covariate in all analysis. Horizontal axis lists the
investigated SNPs, the genes and their chromosomal positions, and the
tagged functional variants based on in silico functional analysis (see also
Table S7). TFBS, transcription factor-binding site; splicing, SNPs that are lo-
cated at 2 base pairs of intron–exon junction region; miRNA, miRNA binding
site activity; nsSNP, SNPs in protein-coding regions that can cause amino acid
change; stop codon, SNPs that may lead to premature termination of pep-
tides (nonsense), which would disable the protein function.
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In the total population, excluding life stressors, the galanin
pathway genes showed minimal relevance (Fig. 2A). This finding
is supported by the moderate/weak genetic main effects in the
initial regression analysis. Next, we performed separate analyses
in subpopulations defined by childhood adversity categories: low
or medium (0–6) versus high (≥7) on the short version of the
Childhood Trauma Questionnaire or by the number of recent
negative life events: low or medium (0–2) versus high (≥3). In
people with exposure to high childhood adversity, the GALR1
diplotypes were highly relevant (Pr = 0.96) with respect to
multiple phenotypes, but it was nonrelevant (Pr = 0.002) in the
low/medium childhood adversity group (Fig. 2B). To compare
the Bayesian posteriors across exposures, we calculated log
posterior ratios. The striking magnitude of the difference is
confirmed by the sixfold log posterior ratio. In contrast, GALR1
showed little relevance to the effect of exposure to recent neg-
ative life events; the GALR1 diplotypes had a relatively low
posterior probability (Pr = 0.27) in the high negative life-events
group, and a negligible posterior probability (Pr = 0.004) in those
with low/medium exposure. (Fig. 2C). The single SNP rs8836
related to GALR2 had high relevance (Pr = 0.75) to multiple
phenotypes in the high negative life-event group but had no
relevance in the low/medium life-events group. This substantial
difference was also indicated by the high log posterior ratio of 4
(Fig. 2D). Although the other galanin pathway genes have only
moderate or low probability of relevance in the high life-stressor
groups, the log posterior ratios (>3) indicate that for each ge-
netic factor there is a substantial difference in terms of posterior
probability of relevance between those who were highly exposed
to environmental life stressors and those who were not (Fig. 2D
and Table S6).
As an interesting comparison, the same Bayesian analysis of
relevance as here used for the galanin system was carried out in
the present cohorts for the well-known 5-HTTLPR polymor-
phism. Note that from the statistical point of view this compar-
ison can be seen as a benchmark and from the systems biological
point of view as a comparison with an experimentally validated
reference. Our results show that the 5-HTTLPR polymorphism is
moderately relevant (Pr = 0.55, log posterior ratio 4.56) in those
who experienced a high level of recent negative life events, and
minimally relevant in those who experienced a high level of
childhood adversities (Pr = 0.04; log posterior ratio 1.67) (Fig. S5).
Fig. 2. Comparison of posterior probabilities of relevance for the total population and for subpopulations under the influence of different environmental
factors. Subpopulations were created by dividing the original sample into two groups based on childhood adversity (CHA) and recent negative life events
(RLE). The posteriors range from 0 to 1 and are estimated with respect to all three phenotypes (reported lifetime depression, current depression, and anxiety).
A high posterior probability indicates that the corresponding factor is highly relevant. GAL, GALR1, and GALR3 represent corresponding diplotypes, whereas
GALR2 denotes the single related SNP. Age and sex were included as cofactors. (A) The posterior probability of relevance of factors for the total population,
not taking into account life stressors. Age and sex are highly relevant, but none of the genetic factors are relevant. (B) The posterior probability of relevance
of factors for patients with low-medium CHA versus patients with high CHA. None of the genetic factors are relevant in the low-medium CHA group. In
contrast, in case of patients with high CHA there is at least one highly relevant genetic factor, the GALR1 with a high posterior probability (Pr = 0.96).
Furthermore, the corresponding log posterior ratio is high (6.09), which means that there is a strong difference between the relevance of GALR1 in the two
subpopulations. (C) A comparison of the posterior probability of relevance of factors in case of patients with low or medium RLE versus patients with high
RLE. In the case of the former subpopulation, none of the genetic factors are relevant, contrary to the high RLE group, where several factors are found to be
relevant. The results indicate that GALR2 is the most relevant factor in case of high RLE having a relatively high posterior probability for relevance (Pr = 0.75).
GALR3 has the second largest probability score, although it is only moderately relevant (Pr = 0.51). Furthermore, GAL and GALR1 are even less relevant, and
can be considered as weak results. (D) To compare the Bayesian posteriors across exposures we calculated log posterior ratios. The high (>3) log posterior
ratios indicate in case of every genetic factor that there is a substantial difference in terms of posterior probability of relevance between those who ex-
perienced high life stresses and who did not. In contrast, the effects of age and sex factors do not differ substantially between those who experienced high
life stresses and who did not.
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In addition, further testing the relevance of the 5-HTTLPR and
the galanin system genes in one model in those who experi-
enced high level of recent negative life events, the relevance of
the galanin system genes remained stable, whereas the rele-
vance of the 5-HTTLPR modestly decreased (from Pr = 0.55 to
Pr = 0.34). This result suggests that the effect of the 5-HTTLPR
may be partially mediated by the galanin system but not vice
versa. These results corroborate previous findings and suggest
that the galanin system probably has similar or stronger effect
on stress-induced depressive symptoms compared with the 5-
HTTLPR functional polymorphism.
Galanin Pathway Level Analysis. To assess the overall contribution
of galanin genes to variation in risk of our depression-related
phenotypes, two general linear models were constructed: a “Re-
duced” model containing only environmental factors (childhood
adversity and recent negative life events), and a “Full” model
containing environmental factors, genetic factors (GAL, GALR1,
GALR2, GALR3), and their interactions. Table 2 shows residual
variances for the phenotypes, namely reported lifetime depres-
sion, current depression, and anxiety separately, and also for the
multivariate case (i.e., combining the variance across all pheno-
types). The results indicate that the Full model explains more
variance, resulting in less residual or unexplained variance in
every case than the life stress-only model. In the overall multi-
variate case the difference is 0.017, which means that the in-
vestigated genetic variants and their interactions with life stressors
contribute 1.7% to the total variance. In our study, the difference
between the Full and Reduced models in the multivariate com-
parison was significant (F = 1.838, Fcritical = 1.759, α < 0.005). This
effect was significant separately for the population recruited in
Budapest (F = 1.632, Fcritical = 1.452, α < 0.05) and in Manchester
(F = 1.531, Fcritical = 1.448, α < 0.05), and in the combined sample
separately both in males (F = 1.645, Fcritical = 1.459, α < 0.05) and
in females (F = 2.108, Fcritical = 2.039, α < 0.0005) with similar
magnitude of effect size (3.9% vs. 3%, respectively). Conducting
the comparison of the models for the phenotypes individually in
the combined sample showed that the difference between the
models was most significant in case of the current depression
phenotype (F = 2.174, Fcritical = 2.031, α < 0.0005).
In Silico Functional Analysis and Comparison with Psychiatric Genetic
Consortium GWAS Results. Finally, in silico functional prediction
was carried out using the SNP Function Prediction (FuncPred)
tool (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm). This pro-
cess revealed that two of our investigated SNPs have functional
effects. Namely, rs11662010 (near to the 5′ end of the GALR1
gene) modifies a transcription factor binding site, and rs8836
(downstream to the GALR2 gene in strong LD with it) has
miRNA binding activity. In addition, our 12 haplotype tag SNPs
captured an additional 23 potentially functional variants within
the galanin system (Fig. 1), suggesting that the genetic regions
covered by our haplotype-tagging SNPs have functional con-
sequences on the gene transcription and translation, thus may
reflect real functional differences (Table S7). In addition, the
Psychiatric Genetic Consortium’s latest mega-analysis showed
several nominally significant associations and trends between
MDD and the GAL, and GALR1 genes (Table S7), further
supporting our results.
Discussion
Galanin is, as revealed in animal experiments, a highly “dynamic”
neuropeptide, frequently showing a robust up-regulation of ex-
pression in response to stress, both under physiological and ex-
treme conditions. We tested the hypothesis that the genetic
effects of the galanin system in the development of depression
and anxiety would be greatest in those exposed to the most life
stress. In the present study, genetic variants of GALR1 signifi-
cantly interacted with childhood adversity, suggesting it also
has a role in neuronal damage and wiring during neuronal
development. The interaction of GALR1 SNPs and childhood
adversity in the regression analysis was confirmed by the
Bayesian multivariate analysis of relevance. Moreover, GALR2
rs8836 significantly moderated the effect of recent negative life
events, also confirmed by the Bayesian analysis. In addition,
GALR3 showed a moderate relevance in interaction with recent
negative life events in our study. Finally, high log posterior ratios
indicated that GAL gene effect was more relevant in the highly
stressed population compared with the low or moderately
stressed subjects. These results indicate that the galanin pathway
has a role in the development of depression in humans but only
in persons exposed to high levels of childhood adversity or recent
Table 1. Demographic and phenotypic characteristic of the sample
Demographics Combined Budapest Manchester
Sex
Female 1,641 (70%) 702 (69%) 939 (70%)
Male 720 (30%) 313 (31%) 407 (30%)
Age (mean ± SEM) 32.8 ± 0.2 31.1 ± 0.3 34.0 ± 0.3
Personal psychiatric history
Reported depression 974 (41%) 217 (21%) 757 (56%)
Recurrent episodes 690 (71%) 118 (54%) 572 (76%)
Ever treated with antidepressant 637 (65%) 70 (32%) 567 (75%)
Reported suicide attempt 285 (12%) 48 (5%) 237 (18%)
Reported anxiety disorder 641 (27%) 202 (20%) 439 (33%)
Reported substance use disorder 130 (6%) 24 (2%) 106 (8%)
Family psychiatric history
Reported depression in immediate blood relatives 632 (27%) 135 (13%) 497(37%)
Symptom scores (range 0–4)
BSI depression (mean ± SEM) 0.85 ± 0.02 0.56 ± 0.02 1.08 ± 0.03
BSI anxiety (mean ± SEM) 0.88 ± 0.02 0.69 ± 0.02 1.02 ± 0.03
Adversities
Recent negative life events (mean ± SEM) 1.22 ± 0.03 1.08 ± 0.04 1.3 ± 0.04
Childhood adversity (mean ± SEM) 3.3 ± 0.07 2.8 ± 0.09 3.7 ± 0.1
BSI, Brief Symptom Inventory.
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negative life events, and that the different receptors have dif-
ferent roles in mediating the effects of different stressors.
The paradigmatic example of a candidate gene interacting
with recent negative life events and childhood adversity is the
serotonin transporter gene (SLC6A4). This gene has a functional
polymorphism in the promoter region (5-HTTLPR) (62), whose
risk variant is associated with a 50% reduction in serotonin
transporter protein and predisposition to depression after neg-
ative life events (63–65), although there are negative studies. In
our study we used this gene as a benchmark and reference for the
Bayesian analysis to allow the comparison of posterior proba-
bilities of relevance. The results of Bayesian analysis supported
the relevance of 5-HTTLPR in stress-related depression, but the
galanin system had a stronger effect. Indeed, the investigated
genetic variants in the galanin pathway and their interactions
with life stressors explained 1.7% of the total variance in the
depression-related phenotypes. This is a large proportion in com-
parison with the 0.6% explained variance by the whole-genome
polygenic risk score seen in a recent GWAS mega-analysis for
MDD (54). According to the Psychiatric Genetic Consortium
suggestion, at least 100,000 MDD cases (plus controls) would be
required to achieve GWAS-significant findings for MDD (54).
However, our results further emphasize that using subjects with
high life stresses, because MDD is a stress-related disorder, could
potentially decrease the required number of cases to 5,500–35,000
(Table S3). According to the differential sensitivity hypothesis (57),
some risk genotype-by-stress interactions also involve increased
sensitivity to beneficial environments, such as social supports.
However, no protective effects of galanin-related genotypes were
seen in the low-stress groups in our study.
Potential mechanisms that may explain the galanin system
effect in the development of depression are summarized in Fig. 3.
The GAL gene is widely expressed in the human brain [e.g.,
LC, forebrain, amygdala, and hypothalamus (26, 51)], but its
involvement in the development of depression is not well un-
derstood. Although previous studies indicated that it might have
a sex- or estrogen-dependent effect (49), in our study the galanin
system genetic variants significantly influenced the depression-
related phenotypes both in males and in females, with similar
magnitude of effect size, providing evidence that the excessive
stress effect is not mediated by sex.
The monoamine neurotransmitters, NA, 5-HT, and dopamine,
have been implicated in the mechanism of action of anti-
depressants and thus the pathogenesis of MDD for more than
half a century, and also shown to interact in intricate ways in the
development and treatment of this serious disease (6, 7, 66).
Some of the effects of galanin may fit into this framework. In-
volvement of the galanin system in regulation of mood-related
behavior in animals has focused on several brain sites, via dif-
ferent mechanisms. For example, in rat galanin may have a pro-
depressive role via modulating 5-HT1A receptors in the forebrain
(37, 67) or, when released from soma and dendrites in the LC,
via inhibitory GALR1 autoreceptors (68, 69). The same receptor
mediates inhibition of pyramidal neurons in the ventral hippo-
campus (70). Thus, galanin may cooperate with its cotransmitter
norepinephrine, both at the LC cell body autoreceptor level and
postsynaptically in the hippocampus. However, it is important to
note that recent studies demonstrated that in humans GALR3
receptors are more prevalent in the brainstem compared with
GALR1, whereas GALR1 is widely expressed in the human
forebrain (26). In the 5-HT neuron-rich rat dorsal raphe nucleus/
periaqueductal gray, Lu et al. (39) have suggested that mood is
controlled through a balance between signaling via prodepressive
GALR1/3 (71, 72) and antidepressive GALR2 receptors (38, 39).
In the ventral tegmental area galanin inhibits dopamine neurons,
inducing depression-like behavior (40).
Accumulating evidence suggests that hippocampal atrophy
and loss of dendritic spine synapses are associated with de-
pressive symptoms (73–75), whereas recovery of MDD patients
involves normalization of the hippocampal volume (76), possibly
related to enhancement of functional synapses (77–79). In-
terestingly, galanin has been reported to act as a neuroprotective
factor for hippocampal neurons (80–82) via GalR2 (83). More-
over, it is now established that adult neural stem/progenitor cells
generate new neurons in, for example, the hippocampal granule
cell layer (84, 85). Subsequently, the proliferation and integra-
tion of neuronal stem cells in this brain region have emerged as
a focus in attempts to understand mechanisms underlying stress,
depression, and the effects of antidepressants (86–88). In the
hippocampus, galanin’s trophic and proliferative effects via
GALR2/3 receptors, on neuronal stem cells in the subgranular
zone in the dentate gyrus (89–91), may be involved and could
mediate some of the effects of genetic variation that we have
observed. The latter idea has gained more weight in view of the
recent report that, in humans, a large subpopulation of hippo-
campal neurons, constituting one-third of the neurons, is subject
to exchange (92), substantiating the first report of adult neuro-
genesis in humans (93). Thus, in adults 700 neurons are added in
the hippocampus each day, and around one-third of the hippo-
campal neurons constantly renew, involving most neurons in the
dentate gyrus (92). Interestingly, galanin was more abundant in
mouse embryonic stem cells compared with any other examined
tissues (94), and in human stem cells galanin was in the top 50
overexpressed genes (95). Furthermore, galanin receptors can
also act through cAMP formation (96), and thus the cyclic AMP-
responsive element binding (CREB) signaling pathway (97–99),
Fig. 3. Galanin mechanisms hypothetically involved in MDD in humans.
Galanin, a neuropeptide, and its receptors are colocalized in some mono-
aminergic neurons in the brain. The galanin system is highly sensitive to
experimental and naturalistic stressors. Stress-induced activation of the
galanin system represents the first phase in the development of depression.
Recent analysis of human brain has shown that the Gi protein-coupled
GALR3 (and not GALR1 as in rodents) is the main galanin receptor in NA-LC
and probably 5-HT dorsal raphe nucleus cells, and that the Gi protein-coupled
GALR1 is the main receptor in the forebrain. Antidepressive effects may be
achieved by (i) GALR3 antagonists (71), by reinstating normal monoamine
turnover in the brainstem, and by (ii) GALR1 antagonists in the forebrain by
normalization of limbic system activity, or by (iii) agonists at GALR2, a Gq
protein-coupled receptor, promoting neuroprotection. The present genetic
analysis suggests that GALR1 risk variants may compromise galanin signaling
during childhood, whereas GALR2 signaling may be influenced by recent
negative life events. In addition, all four galanin system genes have relevant
roles in the development of depression-related phenotypes in those persons
who were highly exposed to life stressors.
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which is an important modulator of the brain-derived neuro-
trophic factor (BDNF) production. BDNF mediates activity-de-
pendent neuroplasticity in the hippocampus and cortex, which is
critical to the adaptation of environmental stress and also con-
tribute to antidepressant effects (77, 100, 101). It is interesting to
note that our previous study demonstrated that genetic variation
in the CREB1-BDNF-NTRK2 pathway also interacts with child-
hood adversity to increase risk of depression (102).
There are some limitations of our study. For example, we used
self-reported questionnaires to measure lifetime depression,
depressive and anxiety symptoms, and negative life events that,
although proven and widely used, might be influenced by recall
bias. Therefore, we validated them in a subpopulation of 142 during
face-to-face interviews showing good reliability (102, 103). In
addition, we did not control for the timing of depression and life
events. It has been demonstrated that childhood adversity has
a long-term effect on the pathogenesis of depression (104), and
the questionnaire we used to measure recent (last year) negative
life events builds on items with long-term contextual threat
(105). Finally, our nominally significant G×E interaction results
did not survive traditional correction for multiple testing, which
was expected in case of weak genetic effects. However, our Bayesian
network-based approach accommodates multiple interdependent
outcome variables and predictors (i.e., system genes and life
stresses), minimizes the loss of power, and quantitatively char-
acterizes the dependency structure of galanin G×E interactions.
Results were also confirmed by conventional multivariate anal-
ysis using general linear models and comparatively evaluated
against the 5-HTTLPR as reference. Thus, development of prob-
abilistic graphical model-based methods using Bayesian statisti-
cal framework may be essential for detecting G×E interactions in
modestly heritable disorders.
In conclusion, the present results indicate that the galanin
system plays a significant role in the pathogenesis of depression,
almost entirely by modulating the vulnerability to early and recent
psychosocial stress. The results validate the galanin system as an
illness-related target for novel antidepressant drug development.
In addition, our results support suggestions that G×E inter-
actions may significantly contribute to the “missing heritability”
in genome-wide case-control studies that lack environmental
measures because of their large scale.
Methods
Population. Population cohorts were recruited in Budapest, Hungary and
Manchester, United Kingdom in the European Union-funded NewMood
study (New Molecules in Mood Disorders, Sixth Framework Program of the
European Union, LSHM-CT-2004-503474) using harmonized phenotyping
and genotyping methods that enabled us to carry out a mega-analysis.
From the recruited n = 2,588 subjects, n = 2,361 (n = 1,015 from Budapest
and n = 1,346 from Manchester) were eligible for this study who filled out
the questionnaires, provided DNA, which was successfully genotyped for the
galanin pathway, and have European White ethnic origin. Data of all eli-
gible participants were included in the analysis, regardless of reported psy-
chiatric disorders (Table 1). Details of the recruitment strategy and the
population cohorts can be read in previous publications (64, 102, 103). In
short, we recruited participants aged between 18–60 y from Greater
Manchester, United Kingdom through general practices, advertisements,
and a Web site, and from Budapest, Hungary, through general practices
and advertisements. Participants returning the signed consent form and
the questionnaire were then sent a genetic sampling kit, which they
returned. Both studies were approved by the local ethics committees and
were carried out in accordance with the Declaration of Helsinki. All par-
ticipants provided written informed consent.
Phenotypic Assessment. Three stress-related phenotypic outcome variables
were analyzed. Reported lifetime depression was derived from targeted
questions of a self-reported questionnaire and was validated in a subpopu-
lation during face-to-face diagnostic interviews (102). To measure current
depression and anxiety we used the Brief Symptom Inventory (106) anxiety
and depression subscales with additional items for depression. A short ver-
sion of the Childhood Trauma Questionnaire (107) assessed the experience
of emotional and physical abuse and neglect in childhood, as validated in a
previous study (102). Recent stressors were assessed using a validated mea-
sure of negative life events covering intimate relationships, financial diffi-
culties, illnesses/injuries, and social network problems (105). Further details
of the phenotypic measures can be seen in SI Methods.
Table 2. Residual variances for the full models and the reduced models
Models
Variance
Reported lifetime
depression Current depression Current anxiety Multivariate
Total sample
Reduced 0.215 0.727 0.710 0.551
Full 0.210 0.701 0.692 0.534
Explained variance 0.6% 2.7%* 1.8%† 1.7%‡
Budapest
Reduced 0.154 0.418 0.464 0.345
Full 0.147 0.387 0.440 0.325
Explained variance 0.7% 3.1%‡ 2.4% 2.1%†
Manchester
Reduced 0.225 0.888 0.882 0.665
Full 0.216 0.844 0.843 0.634
Explained variance 0.9% 4.4%† 4.0%† 3.1%†
Total males
Reduced 0.196 0.554 0.501 0.417
Full 0.184 0.501 0.450 0.378
Explained variance 1.2% 5.2%† 5.1%‡ 3.9%†
Total females
Reduced 0.227 0.803 0.798 0.609
Full 0.220 0.759 0.759 0.579
Explained variance 0.7% 4.4%* 3.9%* 3.0%*
*Significant difference in explained variance P < 0.001.
†Significant difference in explained variance 0.01 < P ≤ 0.05.
‡Significant difference in explained variance 0.001 ≤ P ≤ 0.01.
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Genetic Data. Genetic samples (buccal mucosa cells) were collected according
to a validated method (108). Because there are no known functional poly-
morphisms within this pathway we used haplotype tagging method (www.
broad.mit.edu/personal/jcbarret/haploview) to represent the selected genes
and scientific literature to identify previously investigated SNPs. Our hap-
lotype-tagged SNPs capture genetic regions that tend to inherit together
(LD r2 > 0.8) in populations with European ancestry [based on the Centre
d’Etude du Polymorphisme Humain population data of the International
HapMap Project (www.hapmap.org) Phase I. June 2005]. The selected 12
SNPs (Figs. S1–S4 and Table S1) were genotyped with the Sequenom’s
MassARRAY technology (Sequenom, www.sequenom.com). Genotyping was
blinded with regard to phenotype and was performed under the ISO 9001:2000
requirements.
Statistical Analysis. PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink) was
used to test additive genetic association using linear and logistic regression
models, G×E interactions, to impute haplotypes (Table S2), and to calculate
Hardy–Weinberg equilibrium P values. Bayesian and non-Bayesian multivariate
analyses were performed to assess the joint effect of GAL, GALR1, GALR2, and
GALR3 on all three phenotypes (reported lifetime depression, current de-
pression, and anxiety). Non-Bayesian statistical analyses were performed with
SPSS 21.0 for Windows (IBM). Age and sex were covariates in all analyses.
All statistical testing used two-tailed P = 0.05 threshold. For detailed
description of the statistical methods and for power calculations, see SI
Methods. First, we carried out statistical analysis in the total sample
because of the moderate sample size, and then replicated our main findings
in subpopulations according to study sites (Budapest and Manchester) and sex
(female and male).
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